Literature DB >> 32492155

Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation.

Yoshihiro Inamoto1,2, Paul J Martin2, Stephanie J Lee2, Amin A Momin3, Laura Tabellini2, Lynn E Onstad2, Joseph Pidala4, Mary E D Flowers2, Richard L Lawler2, Hiroyuki Katayama3, Samir Hanash3, John A Hansen2.   

Abstract

To identify plasma biomarkers associated with fibrotic mechanisms of chronic graft-versus-host disease (GVHD), we used multiplex mass spectrometry with pooled samples for biomarker discovery in comparing proteomic profiles between patients with newly diagnosed sclerotic chronic GVHD (n = 21), those with newly diagnosed nonsclerotic chronic GVHD (n = 33), and those without chronic GVHD (n = 20). Immunoassay was used to measure protein concentrations of individual discovery samples and 186 independent verification samples. The discovery mass spectrometry analysis identified 2 candidate proteins with at least 1.5-fold difference in sclerotic GVHD: Dickkopf-related protein 3 (DKK3) and interleukin-1 receptor accessory protein (IL1RAP). Analysis of individual discovery samples by immunoassay showed that DKK3, a modulator of the Wnt signaling pathway, was a biomarker for both sclerotic and nonsclerotic chronic GVHD. Verification analysis of 186 patients confirmed that elevated plasma DKK3 concentrations were associated with chronic GVHD, regardless of the presence or absence of sclerosis, and that the area under the receiver operating characteristic curve was 0.85 for association of DKK3 concentrations with chronic GVHD. Multiple linear regression analysis showed that chronic GVHD with or without steroid treatment and patient age were independently associated with DKK3 concentrations. Patients with high DKK3 concentrations had a higher nonrelapse mortality than those with low concentrations. The lower IL1RAP concentrations in patients with sclerotic GVHD compared with other conditions in the discovery cohort were not confirmed in the verification cohort. DKK3 is a novel biomarker for chronic GVHD. Further studies are needed to determine the biological functions of DKK3 in the pathogenesis of chronic GVHD.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32492155      PMCID: PMC7284089          DOI: 10.1182/bloodadvances.2020001485

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  32 in total

1.  Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.

Authors:  Stephanie J Lee; Tam D Nguyen; Lynn Onstad; Merav Bar; Elizabeth F Krakow; Rachel B Salit; Paul A Carpenter; Morgani Rodrigues; A Marcie Hall; Barry E Storer; Paul J Martin; Mary E Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-10       Impact factor: 5.742

2.  Dickkopf-3 acts as a modulator of B cell fate and function.

Authors:  Julia Ludwig; Giuseppina Federico; Sandra Prokosch; Günter Küblbeck; Sabine Schmitt; Alexandra Klevenz; Hermann-Josef Gröne; Lars Nitschke; Bernd Arnold
Journal:  J Immunol       Date:  2015-02-11       Impact factor: 5.422

3.  Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis.

Authors:  Giuseppina Federico; Michael Meister; Daniel Mathow; Gunnar H Heine; Gerhard Moldenhauer; Zoran V Popovic; Viola Nordström; Annette Kopp-Schneider; Thomas Hielscher; Peter J Nelson; Franz Schaefer; Stefan Porubsky; Danilo Fliser; Bernd Arnold; Hermann-Josef Gröne
Journal:  JCI Insight       Date:  2016-01-21

4.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

5.  Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.

Authors:  Jacob Rozmus; Amina Kariminia; Sayeh Abdossamadi; Barry E Storer; Paul J Martin; Stephanie J Lee; Daniel Wolff; Mukta Arora; Corey Cutler; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-14       Impact factor: 5.742

Review 6.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

7.  Biomarker Panel for Chronic Graft-Versus-Host Disease.

Authors:  Jeffrey Yu; Barry E Storer; Kushi Kushekhar; Mohammad Abu Zaid; Qing Zhang; Philip R Gafken; Yuko Ogata; Paul J Martin; Mary E Flowers; John A Hansen; Mukta Arora; Corey Cutler; Madan Jagasia; Joseph Pidala; Betty K Hamilton; George L Chen; Iskra Pusic; Stephanie J Lee; Sophie Paczesny
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

Review 8.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

Review 9.  Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics.

Authors:  Muhammad Haseeb; Rameez Hassan Pirzada; Qurat Ul Ain; Sangdun Choi
Journal:  Cells       Date:  2019-11-03       Impact factor: 6.600

10.  Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Authors:  Jing Du; Ryan Flynn; Katelyn Paz; Hong-Gang Ren; Yuko Ogata; Qing Zhang; Philip R Gafken; Barry E Storer; Nathan H Roy; Janis K Burkhardt; Wendy Mathews; Jakub Tolar; Stephanie J Lee; Bruce R Blazar; Sophie Paczesny
Journal:  Blood       Date:  2018-01-18       Impact factor: 25.476

View more
  5 in total

1.  Sclerotic chronic GVHD: you may WANT to block WNT.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

Review 2.  Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.

Authors:  Sanaz Keshavarz Shahbaz; Amir Hossein Mansourabadi; Davood Jafari
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 4.330

Review 3.  Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.

Authors:  Alan Bidgoli; Brittany Paige DePriest; Maedeh Vakili Saatloo; Hua Jiang; Denggang Fu; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2022-07-11

4.  Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.

Authors:  Sanaz Keshavarz Shahbaz; Amir Hossein Mansourabadi; Davood Jafari
Journal:  Clin Exp Immunol       Date:  2022-02-08       Impact factor: 5.732

Review 5.  Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?

Authors:  Martino Introna; Josée Golay
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.